Dipeptides, E.g., Aspartame, Anserine, Carnosine, Etc. Patents (Class 260/998.2)

Cross-Reference Art Collections

Aspartylphenylalanone esters and cyclohexylalanine esters (Class 260/998.21)
Arginine containing (Class 260/998.22)
  • Treatment with opioid antagonists and mTOR inhibitors
    Patent number: 10383869
    Abstract: Embodiments of the invention provide methods of treating a disorder or disease characterized by cellular proliferation and migration by co-administering a synergistically effective amount of an mTOR inhibitor and a ?-opioid receptor antagonist.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 20, 2019
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Jonathan Moss, Patrick A. Singleton
  • Chemically-modified peptides, compositions, and methods of production and use
    Patent number: 6858581
    Abstract: Compositions and methods for inhibiting and controlling the growth of microbes are disclosed. The composition comprises at least one chemically-modified peptide with antimicrobial activity and at least one carrier. The method comprises of administering an amount, effective for the prevention, inhibition and termination of microbial growth for industrial, pharmaceutical, household and personal care use.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: February 22, 2005
    Assignee: Arizona State University
    Inventors: Carla H. Kuhner, James A. Romesser
  • Selective MMP inhibitors having reduced side-effects
    Patent number: 6818622
    Abstract: The subject invention pertains to matrix metalloproteinase (MMP) inhibitors that exhibit an IC50 of below 10−4M against MMP and have substantially no activity against non-MMP metalloproteinase-related events. The MMP inhibitors of the invention have reduced side-effects, especially with respect to joint pain.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: November 16, 2004
    Assignee: Darwin Discovery Ltd.
    Inventors: John Bird, John Gary Montana, Ruth Elizabeth Wills, Andrew Douglas Baxter, David Alan Owen
  • Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
    Patent number: 6566338
    Abstract: The use of caspase inhibitors for treating, ameliorating, and preventing non-cancer cell death during chemotherapy and radiation therapy and for treating and ameliorating the side effects of chemotherapy and radiation therapy of cancer is disclosed.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: May 20, 2003
    Assignee: Cytovia, Inc.
    Inventors: Eckard Weber, Gordon B. Mills, Douglas R. Green
  • Localized use of nitric oxide-adducts to prevent internal tissue damage
    Patent number: 6255277
    Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: July 3, 2001
    Assignees: Brigham and Women's Hospital, NitroMed, Inc.
    Inventors: Jonathan Stamler, Joseph Loscalzo, John D. Folts
  • Dipeptide apoptosis inhibitors and the use thereof
    Patent number: 6184210
    Abstract: The present invention is directed to novel dipeptides thereof, represented by the general Formula I: where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: February 6, 2001
    Assignee: Cytovia, Inc.
    Inventors: John F. W. Keana, Sui Xiong Cai, John Guastella, Wu Yang, John A. Drewe
  • Peptidyl compounds
    Patent number: 6180611
    Abstract: Compounds of general formula (I): have utility as inhibitors of matrix metalloproteinases and TNF.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: January 30, 2001
    Assignee: Darwin Discovery, Ltd.
    Inventors: John Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson, Neil Phillipson